Rajpal Arvind, Beyaz Nurten, Haber Lauric, Cappuccilli Guido, Yee Helena, Bhatt Ramesh R, Takeuchi Toshihiko, Lerner Richard A, Crea Roberto
Bioren Inc., 100 Glenn Way, Suite 1, San Carlos, CA 94070, USA.
Proc Natl Acad Sci U S A. 2005 Jun 14;102(24):8466-71. doi: 10.1073/pnas.0503543102. Epub 2005 Jun 6.
Look-through mutagenesis (LTM) is a multidimensional mutagenesis method that simultaneously assesses and optimizes combinatorial mutations of selected amino acids. The process focuses on a precise distribution within one or more complementarity determining region (CDR) domains and explores the synergistic contribution of amino acid side-chain chemistry. LTM was applied to an anti-TNF-alpha antibody, D2E7, which is a challenging test case, because D2E7 was highly optimized (K(d) = 1 nM) by others. We selected and incorporated nine amino acids, representative of the major chemical functionalities, individually at every position in each CDR and across all six CDRs (57 aa). Synthetic oligonucleotides, each introducing one amino acid mutation throughout the six CDRs, were pooled to generate segregated libraries containing single mutations in one, two, and/or three CDRs for each V(H) and V(L) domain. Corresponding antibody libraries were displayed on the cell surface of yeast. After positive binding selection, 38 substitutions in 21 CDR positions were identified that resulted in higher affinity binding to TNF-alpha. These beneficial mutations in both V(H) and V(L) were represented in two combinatorial beneficial mutagenesis libraries and selected by FACS to produce a convergence of variants that exhibit between 500- and 870-fold higher affinities. Importantly, these enhanced affinities translate to a 15- to 30-fold improvement in in vitro TNF-alpha neutralization in an L929 bioassay. Thus, this LTM/combinatorial beneficial mutagenesis strategy generates a comprehensive energetic map of the antibody-binding site in a facile and rapid manner and should be broadly applicable to the affinity maturation of antibodies and other proteins.
通透诱变(LTM)是一种多维诱变方法,可同时评估和优化所选氨基酸的组合突变。该过程聚焦于一个或多个互补决定区(CDR)结构域内的精确分布,并探索氨基酸侧链化学的协同作用。LTM被应用于抗TNF-α抗体D2E7,这是一个具有挑战性的测试案例,因为D2E7已被其他人高度优化(解离常数K(d)=1 nM)。我们在每个CDR的每个位置以及所有六个CDR(共57个氨基酸)中分别选择并引入了代表主要化学功能的九个氨基酸。将每个在六个CDR中引入一个氨基酸突变的合成寡核苷酸汇集在一起,以生成针对每个V(H)和V(L)结构域在一个、两个和/或三个CDR中包含单突变的分离文库。相应的抗体文库展示在酵母细胞表面。经过阳性结合筛选,在21个CDR位置鉴定出38个取代,这些取代导致与TNF-α的结合亲和力更高。V(H)和V(L)中的这些有益突变体现在两个组合有益诱变文库中,并通过荧光激活细胞分选(FACS)进行选择,以产生亲和力提高500至870倍的变体趋同。重要的是,这些增强的亲和力在L929生物测定中转化为体外TNF-α中和能力提高15至30倍。因此,这种LTM/组合有益诱变策略以简便快捷的方式生成了抗体结合位点的全面能量图谱,应广泛适用于抗体和其他蛋白质的亲和力成熟。